Clinical trial · Interventional
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds normally found circulating in the blood. The nutrients (glucose, fructose, glutamine, acetate, and lactate) are also found in common foods. A nutrient tracer will be given to the participants through an intravenous (IV) catheter during surgery or biopsy, and blood will be collected every 30 minutes during the infusion to monitor safety parameters and the nutrient tracers. The investigators will collect a tissue sample after the completion of surgery. Participants not having an infusion will have their tissue collected after surgery or biopsy. Participation in this study will not change patient care. All patients will receive standard of care treatment as determined by their doctors.
Conditions
Conditions (12)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chromophobe Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Clear Cell Carcinoma | Clear Cell Adenocarcinoma | CURATED_BROADER | 0.80 |
| Fumarate Hydratase Deficiency | — | UNRESOLVED | — |
| Hereditary Leiomyomatosis and Renal Cell Cancer | Hereditary Leiomyomatosis and Renal Cell Carcinoma | ALIAS | 0.90 |
| HLRCC | Hereditary Leiomyomatosis and Renal Cell Carcinoma | ALIAS | 0.90 |
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Kidney Cancer | Malignant Kidney Neoplasm | CURATED_BROADER |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 13C-Acetate | Other | — | UNRESOLVED |
| 13C-Fructose | Other | — | UNRESOLVED |
| 13C-Glucose | Other | — | UNRESOLVED |
| 13C-Glutamine | Other | — | UNRESOLVED |
| 13C-Lactate | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- EXPERIMENTAL
- label
- 13C-Glucose
- interventionNames
- Other: 13C-Glucose
- type
- EXPERIMENTAL
- label
- 13C-Acetate
- interventionNames
- Other: 13C-Acetate
- type
- EXPERIMENTAL
- label
- 13C-Lactate
- interventionNames
- Other: 13C-Lactate
- type
- EXPERIMENTAL
- label
- 13C-Glutamine
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have radiographic evidence of known or probable kidney or urothelial cancer requiring surgical biopsy or excision. * Age ≥ 18 years * Subjects of all races and ethnic origins * The willingness to sign and ability to understand a written informed consent. * Patients participating in other clinical trials are eligible, and will be evaluated on a case by case basis by the Principal Investigator, Dr. Vitaly Margulis, MD. Exclusion Criteria: * Uncontrolled or poorly controlled diabetes for patients receiving a 13C infusion * Pregnant or breastfeeding * Not a surgical candidate
References
Publications (0)
Data not yet available